Walter Reed Bethesda Joins Novilase Clinical Trial

Groundbreaking Study of Laser Treatment for Breast Cancer Now Has 11 Active Trial Sites in United States and United Kingdom

CHICAGO--()--Novian Health, developer of Novilase® Breast Therapy, announced today that Walter Reed National Military Medical Center (Bethesda, Md.) is now a participating study site in the BR-002 Novilase Clinical Trial. The multi-center study is evaluating the effectiveness of Novilase Breast Therapy as an alternative to lumpectomy surgery for the treatment of small, early-stage breast cancers. Novian Health has already received FDA clearance for the use of Novilase Breast Therapy as an alternative to surgery for the treatment of benign breast tumors (fibroadenomas).

“Patients appreciate taking part in this clinical trial because they know they’re contributing to the possible improvement of breast cancer treatment in the future”

"Patients appreciate taking part in this clinical trial because they know they’re contributing to the possible improvement of breast cancer treatment in the future,” said Barbara Schwartzberg, M.D. “Because our enrollees have stepped forward, women someday may be able have their tumors treated as a convenient outpatient procedure, instead of an invasive surgery with anesthesia and a long recuperation."

Dr. Schwartzberg is principal investigator of the BR-002 Novilase Clinical Trial. She is also the principal investigator at Rose Medical Center (Denver, Col.), one of the 11 breast centers in the BR-002 breast cancer study.

Known as “the Nation’s Medical Center,” Walter Reed National Military Medical Center in Bethesda, Maryland serves military families, active duty personnel, returning war heroes, veterans, and the nation’s leaders.

Col. Craig D. Shriver, M.D., U.S. Army, is the principal investigator for the BR-002 Novilase Clinical Trial at Walter Reed, where he directs the institution’s Murtha Cancer Center.

In addition to Walter Reed, ten other sites have been enrolling patients for the early-stage breast cancer study. The sites include:

  • Rose Medical Center – Rose Breast Center (Denver, Col.)
    Principal Investigator: Dr. Barbara Schwartzberg
  • Alexian Brothers Health System – St. Alexius Breast Care Center (Bartlett, Ill.)
    Principal Investigator: Dr. Robert Maganini
  • Broomfield Hospital – Mid Essex Hospital NHS Trust (Chelmsford, UK England)
    Principal Investigator: Mr. Simon Smith
  • Wheaton Franciscan Health System (Milwaukee, Wisc.)
    Principal Investigator: Dr. Hanadi Bu-Ali
  • Southmead Hospital – North Bristol NHS Trust (Bristol, UK England)
    Principal Investigator: Dr. Michael Shere
  •  Advocate Lutheran General Hospital – Caldwell Breast Center (Park Ridge, Ill.)
    Principal Investigator: Dr. Heidi Memmel
  • The Breast Center of Southern Arizona (Tucson, Ariz.)
    Principal Investigator: Dr. Eric Whitacre
  • Norfolk and Norwich University Hospitals – NHS Foundation Trust (Norwich, UK England)
    Principal Investigator: Dr. Arne Juette
  • Columbia University Medical Center – Department of Surgery (New York, N.Y.)
    Principal Investigator: Dr. Margaret Chen
  • University of Toledo (Toledo, Ohio)
    Principal investigator: Dr. Helen Mabry

Novilase Breast Therapy is an image-guided, minimally invasive alternative for lumpectomy that uses heat from a laser to ablate (destroy) small breast tumors. The BR-002 Novilase Clinical Trial is evaluating the rate of complete tumor ablation of breast cancers that are up to 2 centimeters. It is also examining the correlation of the pathology of post-ablation lumpectomy specimens with MRI, ultrasound and mammography in detecting any residual tumor.

If the multi-center trial and subsequent trials are successful, Novilase Breast Therapy may provide women who have early-stage breast cancer with a treatment option that has several potential advantages, including:

  • Fewer re-treatments or repeat surgeries
  • Minimal scarring or changes in the contour of breast tissue
  • Less risk of infection
  • Shorter recovery time and quicker return to normal activities

Novilase Breast Therapy does not preclude any additional treatment, if necessary. For example, radiation therapy, systemic adjuvant therapy, or any other treatment that is medically indicated can still be used.

About Walter Reed National Military Medical Center

Walter Reed National Military Medical Center provides medical care to our wounded, ill and injured service members and service members and their families. Walter Reed Bethesda is the Nation’s Medical Center, proudly serving military beneficiaries in the Washington, D.C. area as well as those from across the country and around the globe. As the largest military medical center in the U.S., it is a tertiary care destination providing services in over 100 clinics and specialties and is the first destination in the continental United States for caring for the wounded, ill and injured from global conflicts.

For more information about Walter Reed National Military Medical Center, access http://bit.ly/1m2nVI9. For more information about the Department of Defense Breast Care & Research Center, access http://bit.ly/1r18new.

About Novilase

Novilase Breast Therapy is a laser-based, minimally invasive device for destroying tumors. It provides an alternative to conventional surgery while preserving the patient's options for additional procedures or adjunctive therapies. The image-guided outpatient procedure does not require general anesthetic or a hospital stay. To join or learn more about the BR-002 Novilase Clinical Trial, call 888-702-3198 or access www.novilase.com.

About Novian Health

Novian Health Inc., based in Chicago with a subsidiary in Evry, France, is a privately held medical device company with proprietary technology for the treatment of tumors using Interstitial Laser Therapy. Developed as an alternative to surgery, the company's technology uses parametrically controlled heating for the ablation of tumors. Image-guided treatment of breast tumors is the first application of the technology, with the potential for Novilase to treat tumors elsewhere in the body. Novian Health has received U.S. FDA 510(k) clearance for the treatment of benign breast tumors. For more information, call (312) 266-7200 or access www.novianhealth.com.

Contacts

Dowling & Dennis Public Relations
Liz Dowling, 415-388-2794
Liz@DowlingDennis.net

Website